Effect of docetaxel + oxaliplatin + S-1 and docetaxel + cisplatin + fluorouracil on treatment of advanced gastric cancer

• Main Authors: Wei Li, Peng Zhao
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2016-09-01
• Series: Journal of Hainan Medical University
• Subjects: Advanced gastric cancer; Progression-free survival; Overall survival; Tumor markers; Angiogenesis; Invasion
• Online Access: http://www.hnykdxxb.com/PDF/201617/25.pdf
• ISSN: 1007-1237; 1007-1237

Objective: To compare the effect of docetaxel + oxaliplatin + S-1 and docetaxel + cisplatin + fluorouracil on treatment of advanced gastric cancer. Methods: A total of 496 with advanced gastric cancer who received chemotherapy in our hospital from 2014 to 2015 were selected and randomly divided into DSOX group (docetaxel + oxaliplatin + S-1 group) and DCF model group (docetaxel + cisplatin + fluorouracil group), and the progression-free survival (PFS) and overall survival (OS) were followed up; before chemotherapy and after two cycles of chemotherapy, serum was collected to determine ALT, AST, BUN, CR, CRP, CEA, CA19-9, CA72-4, VEGF, IGF-1, MMP2, MMP7 and MMP9 levels. Results: Median PFS and median OS of DSOX group were longer than those of DCF group; after chemotherapy, serum ALT, AST, BUN, CR and CRP levels of both groups were higher than those before chemotherapy (P<0.05) and serum ALT, AST, BUN, CR and CRP levels were not different between two groups (P>0.05); after chemotherapy, serum CEA, CA19-9, CA72-4, VEGF, IGF-1, MMP2, MMP7 and MMP9 levels of both groups were significantly lower than those before chemotherapy (P<0.05) and serum CEA, CA19-9, CA72-4, VEGF, IGF-1, MMP2, MMP7 and MMP9 levels of DSOX group were significantly lower than those of DCF group (P<0.05). Conclusions: DSOX chemotherapy can prolong progression-free survival and overall survival in patients with advanced gastric cancer and has better killing effect on cancer cells and better inhibiting effect on angiogenesis in gastric cancer tissue and cancer cell invasion than DCF chemotherapy.